Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07469202) titled 'CYTALUX Dose Extension Study' on March 9.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: On Target Laboratories, LLC
Condition:
Cancer in the Lung
Ovarian Cancer
Intervention:
Drug: CYTALUX (pafolacianine) injection
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: May 15, 2026
Target Sample Size: 106
To know more, visit https://clinicaltrials.gov/study/NCT07469202
Published by HT Digital Content Services with permission from Health Daily D...